Perceptive Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Perceptive Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-800,000	Closed	-$29.9M	–	167
2021 Q2	$29.9M	Hold	800,000	–	–	0.39%	57
2021 Q1	$20.5M	Hold	800,000	–	–	0.26%	76
2020 Q4	$17.6M	Hold	800,000	–	–	0.19%	92
2020 Q3	$14.4M	Hold	800,000	–	–	0.21%	76
2020 Q2	$20.3M	Buy	+800,000	New	+$17.2M	0.33%	61
2020 Q1	–	Sell	-36,496	Closed	-$804K	–	136
2019 Q4	$804K	Buy	+36,496	New	+$734K	0.02%	99
2016 Q2	–	Sell	-50,000	Closed	-$268K	–	212
2016 Q1	$268K	Hold	50,000	–	–	0.02%	147
2015 Q4	$594K	Hold	50,000	–	–	0.04%	97
2015 Q3	$411K	Hold	50,000	–	–	0.03%	112
2015 Q2	$698K	Buy	+50,000	New	+$917K	0.04%	126

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Perceptive Advisors's DRNA Position: Q3 2021 in Review

Perceptive Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 800,000 shares — an estimated $29.9M sold.

Perceptive Advisors first reported a position in DRNA in Q2 2015 and held it in 10 quarters. The position peaked at $29.9M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Perceptive Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Perceptive Advisors sold 800,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $29.9M.
Perceptive Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Perceptive Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $29.9M in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.